Arcutis Biotherapeutics Inc (ARQT) 13F Holdings Overview (Q2 2026)

ARQT ranks #2320 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ARQT is a top-conviction position for Pivotal bioVenture Partners Investment Advisor LLC — at 10.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ARQT belongs to Montanova Capital, LLC, but the position matters far more to Pivotal bioVenture Partners Investment Advisor LLC, who has 10.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

California State Teachers Retirement System has added to its ARQT position for two straight quarters, increasing it by $123.3M to reach $126.3M today.

Gilder Gagnon Howe & Co LLC has trimmed its ARQT position for two straight quarters, cutting it by $94.9M while still holding $34.4M.

ARQT is up 0.4% today, and institutions have been net buyers of $174.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ARQT posted net income of $28.5M over the trailing twelve months, and currently trades at a P/E of 106.4.

• Profitable — net income of $28.5M over the trailing twelve months
• Revenue grew 76.1% year over year
• Net income improved year over year, from -$93.3M to $28.5M
• Operating cash flow was negative, using $5.6M in cash
• Current ratio of 3.17x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.29x equity — within a conventional range